Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Transplantation

• Publication date

  2013-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0b013e318276a20ePMID 23380864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early basal insulin therapy decreases new-onset diabetes after renal transplantation.

  2012cited by this paper
• Impaired Glucose Metabolism Despite Decreased Insulin Resistance After Renal Transplantation

  2012influential reference
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• The association of early post-transplant glucose levels with long-term mortality

  2011influential reference
• Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans

  2011cited by this paper
• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  2011cited by this paper
• Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial

  2011cited by this paper
• Pioglitazone and bladder cancer.

  2011cited by this paper
• Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

  2011cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

  2010cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2010cited by this paper
• Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.

  2010cited by this paper
• The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

  2008cited by this paper
• Influence of Lifestyle Modification in Renal Transplant Recipients With Postprandial Hyperglycemia

  2008cited by this paper
• Prediabetes in Patients Receiving Tacrolimus in the First Year After Kidney Transplantation: A Prospective and Multicenter Study

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Nutrition Recommendations and Interventions for Diabetes

  2008cited by this paper
• Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study.

  2008cited by this paper
• Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

  2008cited by this paper
• The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program

  2007cited by this paper
• Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.

  2007cited by this paper
• Impaired Fasting Glucose and Impaired Glucose Tolerance

  2007cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• The Use of Oral Glucose Tolerance Tests to Risk Stratify for New-Onset Diabetes After Transplantation: An Underdiagnosed Phenomenon

  2006influential reference
• Dexamethasone Induces Cell Death in Insulin-Secreting Cells, an Effect Reversed by Exendin-4

  2006cited by this paper
• Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: A sign of impaired beta-cell function?

  2006cited by this paper
• The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events.

  2006cited by this paper
• New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.

  2005cited by this paper
• Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.

  2005cited by this paper
• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  2005cited by this paper
• Pioglitazone in the Management of Diabetes Mellitus after Transplantation

  2004cited by this paper
• Development of diabetes mellitus post-renal transplantation is associated with poor short-term clinical outcomes.

  2003cited by this paper
• Diabetes Mellitus After Kidney Transplantation in the United States

  2003cited by this paper
• Diabetes Mellitus after Kidney Transplantation in the United States

  2003cited by this paper
• A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients.

  2003cited by this paper
• Methods for clinical assessment of insulin sensitivity and β-cell function

  2003cited by this paper
• Methods for clinical assessment of insulin sensitivity and beta-cell function.

  2003cited by this paper
• Diagnosis and classification of diabetes mellitus

  2002cited by this paper
• Subclinical states of glucose intolerance and risk of death in the U.S.

  2001influential reference
• Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients.

  1998cited by this paper
• Pancreatic (cid:1) -cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs

  year unknowncited by this paper

• Comparative efficacy and safety of antidiabetic agents for post-transplant diabetes mellitus: a network meta-analysis

  2025cites this paper
• Comparison of Clinical Outcomes Between Two Types of Dipeptidyl Peptidase-4 Inhibitors in Posttransplant Diabetes Mellitus in Kidney Transplantation Recipients: A Nationwide Population-Based Cohort Study in Korea.

  2025cites this paper
• Continuous glucose monitoring (Dexcom g6) in people with diabetes after kidney transplantation

  2024cites this paper
• An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management

  2024cites this paper
• International consensus on post-transplantation diabetes mellitus

  2024cites this paper
• Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation

  2023cites this paper
• Progress of new-onset diabetes after liver and kidney transplantation

  2023cites this paper
• Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review.

  2022cites this paper
• Sitagliptin Versus Placebo to Reduce the Incidence and Severity of Posttransplant Diabetes Mellitus After Kidney Transplantation—A Single-center, Randomized, Double-blind Controlled Trial

  2022cites this paper
• Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges

  2022cites this paper
• Posttransplant Diabetes Mellitus (PTDM) following solid organ transplantation - Systematic analysis of prevalence and total mortality and meta-analysis of randomized interventional studies aimed at lowering blood glucose.

  2022cites this paper
• Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution.

  2022cites this paper
• Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists

  2022cites this paper
• Urinary dipeptidyl peptidase-4 is a useful marker for tubulitis, and it is released from the tubular cells of kidney transplant recipients

  2022cites this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

  2022cites this paper
• Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach

  2022cites this paper
• Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management

  2021cites this paper
• Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure

  2021cites this paper
• Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update

  2021cites this paper
• Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients

  2021cites this paper
• CD161a-positive natural killer (NK) cells and α-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection.

  2021cites this paper
• Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation.

  2021cites this paper
• Approach to the patient: Early post-renal transplant hyperglycemia

  2021cites this paper
• Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options.

  2020cites this paper
• Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

  2020cites this paper
• Post-Transplantation Diabetes Mellitus

  2020cites this paper
• Metabolic Disorders with Kidney Transplant.

  2020cites this paper
• Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients

  2020cites this paper
• Advances in pharmacotherapy for post-transplant diabetes mellitus

  2020influential citation
• INCRETIN BASED THERAPIES AND SGLT-2 INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS.

  2020cites this paper
• Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy.

  2019cites this paper
• Management of metabolic syndrome and cardiovascular risk after liver transplantation.

  2019cites this paper
• New onset of diabetes after transplant

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper
• Cardiovascular Disease in Renal Transplantation

  2019cites this paper
• Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.

  2019cites this paper
• Kidney Transplant Management

  2019cites this paper
• Complications of Solid Organ Transplantation: Cardiovascular, Neurologic, Renal, and Gastrointestinal.

  2019cites this paper
• Post-transplant diabetes mellitus in patients with solid organ transplants

  2019cites this paper
• Management of diabetes mellitus in patients undergoing liver transplantation

  2019cites this paper
• Non-immunological complications following kidney transplantation

  2019cites this paper
• PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

  2019cites this paper
• Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review

  2018cites this paper
• Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention

  2018cites this paper
• Diabetes in Kidney Transplant Recipients

  2018cites this paper
• Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.

  2018cites this paper
• Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

  2017cites this paper
• Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

  2017cites this paper
• Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

  2017cites this paper
• Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

  2017cites this paper
• Risk assessment and management of post-transplant diabetes mellitus.

  2016cites this paper
• Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study

  2016cites this paper
• Effect of interleukin‐2 receptor antagonists on new‐onset diabetes after liver transplantation: A retrospective cohort study

  2016cites this paper
• Glucometabolic disease in the kidney transplant patient.

  2016cites this paper
• Post-transplantation diabetes-state of the art.

  2016cites this paper
• TACKLING A BIG PROBLEM WITH LITTLE EVIDENCE: IMPROVING RESEARCH INTO POSTTRANSPLANTATION DIABETES.

  2016cites this paper
• HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.

  2016cites this paper
• Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

  2016cites this paper
• POST-TRANSPLANT DIABETES MELLITUS (PTDM)

  2016cites this paper
• Stratégie thérapeutique dans un diabète post-transplantation

  2016cites this paper
• Diabetes Mellitus After Solid Organ Transplantation – An Overview

  2016cites this paper
• Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial

  2015cites this paper
• Diabetes mellitus de novo postrasplante

  2015cites this paper
• Glucose metabolism abnormalities after renal transplantation: studies on epidemiology, mechanisms and outcomes

  2015cites this paper
• Renal posttransplantation diabetes mellitus: An overview.

  2015cites this paper
• Post‐transplantation diabetes mellitus: evaluation of treatment strategies

  2015cites this paper
• Treating posttransplantation diabetes mellitus

  2015cites this paper
• DPP-4 INHIBITOR THERAPY IN PATIENTS AFTER PANCREATIC TRANSPLANT.

  2015cites this paper
• Emerging treatments for post-transplantation diabetes mellitus

  2015cites this paper
• THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).

  2015cites this paper
• Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management.

  2015cites this paper
• Antidiabetic therapy in post kidney transplantation diabetes mellitus.

  2015cites this paper
• Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

  2015cites this paper
• Treatment options for post-transplantation diabetes mellitus.

  2015cites this paper
• The Diagnosis of Posttransplantation Diabetes Mellitus: Meeting the Challenges

  2015cites this paper
• New‐onset diabetes after liver transplantation and its impact on complications and patient survival

  2015cites this paper
• Metformin and other antidiabetic agents in renal failure patients.

  2015cites this paper
• Efficacy and Safety of Vildagliptin in New‐Onset Diabetes After Kidney Transplantation—A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2014cites this paper
• Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment.

  2014cites this paper
• Cardiovascular complications after transplantation: treatment options in solid organ recipients.

  2014cites this paper
• Incretin-based therapies in prediabetes: Current evidence and future perspectives.

  2014cites this paper
• Nachsorge nach Nierentransplantation – Welche Immunsuppression ist für welche Patienten im Langzeitverlauf geeignet?

  2014cites this paper
• Evaluation and Management of Transplant-Associated Hyperglycemia

  2014cites this paper
• Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions

  2014cites this paper
• Diabetes mellitus and renal transplantation in adults: is there enough evidence for diagnosis, treatment, and prevention of new-onset diabetes after renal transplantation?

  2014cites this paper
• Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

  2014cites this paper
• Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.

  2014cites this paper
• New‐onset diabetes after renal transplantation

  2014cites this paper
• Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

  2014cites this paper
• Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation

  2013cites this paper
• Novel views on new-onset diabetes after transplantation: development, prevention and treatment.

  2013cites this paper
• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

  2013cites this paper